Synthesis of Mn2O3 Nanoparticles and Determination of Its Inhibition Effect On Sera of Iraqi Patients with Diabetes Mellitus Type-2 and Diabetes Nephropathy

Abstract

Manganese is essential for the synthesis of antioxidant enzymes and metabolic issues in Diabetes type 2 (DMT2), which is a worldwide disease, Chronic metabolic disorders cause insulin resistance, hyperglycemia, and complications like diabetic nephropathy. Arginase converts arginine to ornithine and urea. Increased arginase activity in DMT2 and diabetes nephropathy (DN)which has been linked to kidney damage, and arginase inhibitors can increase NO which is essential to vascular function. However, the molecular mechanisms of arginased is regulationare in DMT2 and DN are still unclear. This study examined the effect of manganese oxide nanoparticles (Mn2O3NPs) on arginase activity inhibition inserum samples from DMT2 and DN patients. We hypothesized that Mn2O3NPs alter cell redox status and signaling pathways, affecting DMT2 and DN arginase activity. We used a colorimetric assay to measure arginase activity in 80 serum samples from DMT2 and DN patients treated with different MnO2 NP concentrations to test our hypothesis. The current study characterized nanoparticles using various techniques such as IR, SEM, AFM, XRD, and EDX, which found it within nanoscale nature. Our findings are that Mn2O3NPs modulate arginase activity specificity in DM2 samples. SuggestionsMn2O3NPs could be used to develop new treatments for these conditions.